UNSPSC 51361902: Allobarbital

This classification denotes a barbiturate with the molecular formula C10H12N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8NT43GG2HA, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5-di-2-propenyl- but generally known as allobarbital, which bears US NIH Compound Identifier 5842. Allobarbital comes in forms base, epoxide, and sodium. European Medicines Agency schedules Allobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05334MIG.

UNSPSC 51361902 Allobarbital is a Commodity code that in recent state and local procurement activity covers pharmaceutical procurement—specifically naloxone, generic multi-source pharmaceuticals, and over-the-counter products supplied through authorized wholesalers or directly to public health facilities. State and local buying under this code spans county health departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The work involves competitive bidding or proposal responses for pharmaceutical supply contracts, often with quarterly or ongoing delivery schedules to named facilities, compliance with FDA and Drug Supply Chain Security Act requirements, and fixed-fee or net-pricing models. Vendors must maintain specific insurance coverage, cGMP certification, and relationships with authorized drug wholesalers, and contracts typically run two years with optional renewals.

Recent activity includes Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs to support its pharmacy benefit objectives; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, response deadline March 26, 2026) for generic pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. Geographic activity centers on Florida, Texas, and Minnesota, with multistate reach through cooperative purchasing mechanisms.